Halozyme Therapeutics Inc 's Cash & cash equivalent grew by 364.98 % in the Q3 2026 sequentially, faster than Current Liabilities, this led to improvement in Halozyme Therapeutics Inc 's Quick Ratio to 2.12, Quick Ratio remained below Halozyme Therapeutics Inc average.

Within Biotechnology & Pharmaceuticals industry 121 other companies have achieved higher Quick Ratio than Halozyme Therapeutics Inc in third quarter 2026. While Quick Ratio total ranking in the third quarter 2026 has deteriorated compared to the prior quarter from 1698 to 2433.

Explain Quick Ratio?
How much Cash & cash equivalents HALO�s has?
What are HALO�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/HALO/financial-strength

https://api.csimarket.com/api/v1/companies/HALO/fundamentals

https://api.csimarket.com/api/v1/companies/HALO/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

HALO Quick Ratio	(Sep 30 2026) Q3	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3
Y / Y Current Liabilities Change	-39.54 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	156.03 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	2.12	Subscribe	Subscribe	Subscribe	Subscribe
HALO's Total Ranking	# 2433	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	34.63 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	364.98 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio third quarter 2026 Company Ranking
Within:	No.
Biotechnology & Pharmaceuticals Industry	# 122
Healthcare Sector	# 714
Overall Market	# 2433

Quick Ratio Statistics
High	Average	Low
15.22	3.72	0.46
(Jun 30 2020)		(Jun 30 2025)

Financial Statements
Halozyme Therapeutics Inc 's Current Liabilities	$ 506 Millions	Visit HALO's Balance sheet
Halozyme Therapeutics Inc 's Cash & cash equivalent	$ 1,074 Millions	Visit HALO's Balance sheet
Source of HALO's Sales		Visit HALO's Sales by Geography

Cumulative Halozyme Therapeutics Inc 's Quick Ratio

HALO's Quick Ratio for the trailling 12 Months

HALO Quick Ratio	(Sep 30 2026) 12 Months	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	12.8 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	126.07 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	1.23	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 4023	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	-18.88 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	59.84 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to HALO Financial Strength Comparisons >> Go to Compare HALO Quick Ratio to its Competitors

On the trailing twelve months basis HALO Cash & cash equivalent more than doubled by 156.03 % in Q3 2026 year on year, while Current Liabilities grew to $506 millions, this led to increase in in Halozyme Therapeutics Inc 's Quick Ratio to 1.23, Quick Ratio remained below HALO average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 142 other companies have achieved higher Quick Ratio than Halozyme Therapeutics Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 3147 to 4023.

Explain Quick Ratio?
How much Cash & cash equivalents HALO�s has?
What are HALO�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Biotechnology & Pharmaceuticals Industry	# 143
Healthcare Sector	# 900
Within the Market	# 4023

trailing twelve months Quick Ratio Statistics
High	Average	Low
5.58	1.58	0.41
(Dec 31 2012)		(Mar 31 2019)

Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Biotechnology & Pharmaceuticals Industry	Quick Ratio	Sep 30 2026 MRQ Cash & cash equivalent	Sep 30 2026 MRQ Current Liabilities
Replimune Group Inc	5.57	$ 307.833 Millions	$ 55.271 Millions
Denali Therapeutics Inc	5.42	$ 516.196 Millions	$ 95.258 Millions
In8bio Inc	5.32	$ 13.973 Millions	$ 2.628 Millions
Scholar Rock Holding Corp	5.16	$ 413.599 Millions	$ 80.124 Millions
Revolution Medicines Inc	4.81	$ 3,651.385 Millions	$ 758.773 Millions
Caribou Biosciences Inc	4.71	$ 94.881 Millions	$ 20.144 Millions
Recursion Pharmaceuticals Inc	4.47	$ 549.853 Millions	$ 122.918 Millions
Ginkgo Bioworks Holdings Inc	4.33	$ 285.361 Millions	$ 65.849 Millions
Fate Therapeutics Inc	4.26	$ 139.132 Millions	$ 32.691 Millions
Kymera Therapeutics Inc	4.16	$ 373.374 Millions	$ 89.723 Millions
Monte Rosa Therapeutics Inc	4.16	$ 577.726 Millions	$ 139.022 Millions
Vir Biotechnology Inc	4.08	$ 454.635 Millions	$ 111.332 Millions
Moderna Inc	3.93	$ 7,976.000 Millions	$ 2,028.000 Millions
Immunocore Holdings Plc	3.93	$ 901.298 Millions	$ 229.619 Millions
Alector Inc	3.92	$ 138.697 Millions	$ 35.415 Millions
Dbv Technologies S a	3.89	$ 165.700 Millions	$ 42.600 Millions
Regenxbio Inc	3.71	$ 250.976 Millions	$ 67.684 Millions
Tenaya Therapeutics Inc	3.55	$ 66.797 Millions	$ 18.804 Millions
Intensity Therapeutics Inc	3.29	$ 8.494 Millions	$ 2.582 Millions
Adaptive Biotechnologies Corporation	3.02	$ 298.954 Millions	$ 98.967 Millions
Atyr Pharma Inc	2.96	$ 48.751 Millions	$ 16.463 Millions
Precision Biosciences Inc	2.90	$ 81.846 Millions	$ 28.258 Millions
Immunitybio inc	2.86	$ 334.329 Millions	$ 116.795 Millions
Editas Medicine Inc	2.66	$ 190.198 Millions	$ 71.582 Millions
Humacyte Inc	2.61	$ 64.523 Millions	$ 24.761 Millions
Autolus Therapeutics Plc	2.52	$ 248.377 Millions	$ 98.647 Millions
Vericel Corporation	2.44	$ 133.493 Millions	$ 54.719 Millions
Adma Biologics Inc	2.25	$ 124.555 Millions	$ 55.475 Millions
Cullinan Therapeutics Inc	2.20	$ 88.260 Millions	$ 40.130 Millions
Exelixis Inc	2.17	$ 892.018 Millions	$ 411.877 Millions

Date modified: 2026-11-09T06:45:05+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.